ClinicalTrials.gg
CompletedNCT02842866Updated Apr 5, 2022Results posted

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

A Phase 3 interventional study of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine and Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined in Meningitis, Meningococcal Meningitis and Meningococcal Infections, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 36 sites in 2 countries. Open to participants aged 56 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-05.

Primary conditionMeningitis, MeningococcalRegistry: MeningitisReclassifiedWhy we changed it
Registry
Meningitis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Meningitis, Meningococcal
Why
  1. The study's listed conditions name Meningitis, Meningococcal, a narrower term within Meningitis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
907
Allocation
Randomized
Ages
56 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Meningitis, Meningococcal by Sanofi — none open to participants now, none under way, none of them phase 3. Meningitis, Meningococcal · Sanofi.

Enrollment
12th of 23
907 · median 907
Started
2016
with 6 others
Phase 3
13 of 24
none open now
Registered
15th of 24
by date

Among the 24 studies in Meningitis, Meningococcal by Sanofi, this one is the 12th largest by enrollment of the 23 interventional ones that give a count, is one of 7 that started in 2016, is one of 13 in phase 3, and was the 15th registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

None of the 24 studies in Meningitis, Meningococcal by Sanofi is open now. The open studies under Meningitis, Meningococcal, anywhere →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 56 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies in Meningitis, Meningococcal by Sanofi as a file.
02

Study summary

The aim of the study was to demonstrate non-inferiority of immunogenicity and evaluate the safety of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid conjugate vaccine (MenACYW conjugate vaccine) compared to a single dose of Meningococcal Polysaccharide Vaccine Serogroups A, C, Y, and W-135 Combined (Menomune® - A/C/Y/W-135) in adults 56 years of age and older in the United States.

Primary objective:

-To demonstrate the non-inferiority of the vaccine seroresponse to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW conjugate vaccine compared to those observed following the administration of a single dose of Menomune® - A/C/Y/W-135.

Secondary objective:

-To compare the serum bactericidal assay using human complement (hSBA) antibody geometric mean titers of meningococcal serogroups A, C, Y, and W following the administration of MenACYW conjugate vaccine to those observed following the administration of Menomune® - A/C/Y/W-135.

Observational objectives:

  • To describe antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA at baseline (before vaccination) and 30 days after vaccination with MenACYW conjugate vaccine or Menomune® - A/C/Y/W-135 in a subset of 100 participants per treatment group.
  • To describe the safety profile of MenACYW conjugate vaccine compared to that of the licensed Menomune® - A/C/Y/W-135 after a single administration.
Read the detailed description

Participants were randomized in a 1:1 ratio to receive a single dose of MenACYW conjugate vaccine or Menomune® - A/C/Y/W-135 on Day 0 (Visit 1).

Participants underwent immunogenicity assessment at baseline (pre-vaccination) and at 30 to 44 days post-vaccination and were also evaluated for safety up to Day 180 post-vaccination.

03

Conditions studied

  • Meningitis
  • Meningococcal Meningitis
  • Meningococcal Infections

Browse trials for

Keywords

  • Meningitis
  • Meningococcal Meningitis
  • Meningococcal Infections
  • MenACYW conjugate vaccine
  • Menomune® - A/C/Y/W-135
04

In context

Meningitis, Meningococcal Reclassified

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

This study's enrollment of 907 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.

Browse Meningitis, Meningococcal studies →

Lead sponsor

Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.

Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.

First submitted after Sanofi Pasteur became part of Sanofi.

Compared within Meningitis, Meningococcal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Meningitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
56 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥56 years on the day of inclusion.
  • form had been signed and dated.
  • Attended all scheduled visits and complied with all trial procedures.

Exclusion criteria

Exclusion Criteria:

  • Participant was pregnant, or lactating, or of (were considered of non-childbearing potential, a female must be for at least 1 year, surgically sterile, or using an effective method of or abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination).
  • Participation in the 4 weeks preceding the trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
  • Receipt of any vaccine in the 4 weeks (28 days) preceded the trial vaccination or planned receipt of any vaccine prior to Visit 2 except for influenza vaccination, which might be received at least 2 weeks before or after study vaccine. This exception included monovalent pandemic influenza vaccines and multivalent influenza vaccines.
  • Previous vaccination against meningococcal disease with either the trial vaccine or another vaccine (i.e., mono- or polyvalent, polysaccharide, or conjugate meningococcal vaccine containing serogroups A, C, Y, or W; or meningococcal B vaccine).
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months.
  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
  • History of meningococcal infection, confirmed either clinically, serologically, or microbiologically.
  • At high risk for meningococcal infection during the trial (specifically, but not limited to, participants with persistent complement deficiency, with anatomic or functional asplenia, or participants travelling to countries with high endemic or epidemic disease).
  • Known systemic to latex or any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances.
  • Personal history of Guillain-Barré syndrome.
  • Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid-containing vaccine within at least 10 years of the proposed study vaccination.
  • Verbal report of thrombocytopenia, contraindicating IM vaccination, in the Investigator's opinion.
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination in the Investigator's opinion.
  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
  • Current alcohol abuse or drug addiction.
  • Chronic illness that, in the opinion of the investigator, was at a stage where it might interfere with trial conduct or completion.
  • Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature >=100.4 degree [°] Fahrenheit [F]). A prospective participant was not included in the study until the condition had resolved or the febrile event had subsided.
  • Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw.
  • Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
907 participants (actual)

Study arms

  • Experimental
    Group 1: MenACYW Conjugate Vaccine

    Healthy, adult participants aged greater than or equal to (≥) 56 years received a single dose of MenACYW Conjugate Vaccine on Day 0.

    Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine

  • Active comparator
    Group 2: Menomune® Vaccine

    Healthy, adult participants aged ≥56 years received a single dose of Menomune®- A/C/Y/W-135 Vaccine on Day 0.

    Biological: Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined

Interventions

  • BiologicalMeningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine

    0.5 milliliter (mL), Intramuscular (IM), single dose on Day 0.

    Also known as: MenACYW conjugate vaccine

  • BiologicalMeningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined

    0.5 mL, Subcutaneous (SC), single dose on Day 0.

    Also known as: Menomune® - A/C/Y/W-135

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menomune® Vaccine

    Vaccine seroresponse for serogroups A, C, Y, and W was measured by serum bactericidal assay using human complement (hSBA). It was defined as post-vaccination hSBA titers ≥1:16 for participants with pre-vaccination hSBA titers less than (\<) 1:8, or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers ≥1:8.

    Time frame: Day 30 (Post-vaccination)

Secondary outcomes

  1. Geometric Mean Titers (GMTs) of Antibodies Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine or Menomune® Vaccine

    GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA method.

    Time frame: Day 30 (Post-vaccination)

08

Results

Posted Feb 18, 2020

Participant flow

Study was conducted from 15-July-2016 to 13-February-2017 at 35 sites in the United States and Puerto Rico.

Participant flow — Overall Study
MilestoneGroup 1: MenACYW Conjugate VaccineGroup 2: Menomune® Vaccine
Started451455
Vaccinated448453
Completed444452
Not completed73
Withdrew: Serious adverse event01
Withdrew: Protocol violation42
Withdrew: Lost to follow-up20
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryPercentage of Participants With Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menomune® Vaccine

Vaccine seroresponse for serogroups A, C, Y, and W was measured by serum bactericidal assay using human complement (hSBA). It was defined as post-vaccination hSBA titers ≥1:16 for participants with pre-vaccination hSBA titers less than (\<) 1:8, or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers ≥1:8.

Time frame:
Day 30 (Post-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants With Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menomune® Vaccine
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: Menomune® Vaccine
Serogroup A58.2 (53.4 to 62.9)42.5 (37.7 to 47.3)
Serogroup C77.1 (72.9 to 81.0)49.7 (44.8 to 54.5)
Serogroup Y74.4 (70.0 to 78.4)43.4 (38.7 to 48.2)
Serogroup W62.6 (57.8 to 67.2)44.8 (40.0 to 49.6)
Statistical analysis
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: Menomune® Vaccine · Difference in percentage: 15.7 · 95% CI 9.08 to 22.2
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: Menomune® Vaccine · Difference in percentage: 27.5 · 95% CI 21.2 to 33.5
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: Menomune® Vaccine · Difference in percentage: 31.0 · 95% CI 24.6 to 37.0
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: Menomune® Vaccine · Difference in percentage: 17.8 · 95% CI 11.2 to 24.2
SecondaryGeometric Mean Titers (GMTs) of Antibodies Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine or Menomune® Vaccine

GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA method.

Time frame:
Day 30 (Post-vaccination)
Reported as:
Geometric mean · titers (1/dilutions)
Geometric Mean Titers (GMTs) of Antibodies Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine or Menomune® Vaccine
titers (1/dilutions)Group 1: MenACYW Conjugate VaccineGroup 2: Menomune® Vaccine
Serogroup A55.1 (46.8 to 65.0)31.4 (26.9 to 36.7)
Serogroup C101 (83.8 to 123)24.7 (20.7 to 29.5)
Serogroup Y69.1 (58.7 to 81.4)21.0 (17.4 to 25.3)
Serogroup W28.1 (23.7 to 33.3)15.5 (13.0 to 18.4)
Statistical analysis
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: Menomune® Vaccine · Gmt ratio: 1.75 · 95% CI 1.40 to 2.20
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: Menomune® Vaccine · Gmt ratio: 4.10 · 95% CI 3.16 to 5.33
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: Menomune® Vaccine · Gmt ratio: 3.30 · 95% CI 2.57 to 4.23
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: Menomune® Vaccine · Gmt ratio: 1.81 · 95% CI 1.42 to 2.31

Adverse events

Collected over Unsolicited non-serious adverse events (AEs) were collected from Day 0 to Day 30 post-vaccination and solicited reactions (SR) were collected within 7 days post-vaccination. Serious Adverse Events were collected throughout the trial (up to 180 days post-vaccination).. Non-serious events are listed at a 5.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: MenACYW Conjugate Vaccine0/448 (0%)15/448 (3.3%)182/448 (40.6%)
Group 2: Menomune® Vaccine2/453 (0.4%)15/453 (3.3%)121/453 (26.7%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventGroup 1: MenACYW Conjugate VaccineGroup 2: Menomune® Vaccine
OsteoarthritisMusculoskeletal and connective tissue disorders2/4480/453
Acute Myocardial InfarctionCardiac disorders0/4482/453
Atrial FibrillationCardiac disorders1/4480/453
Colitis IschaemicGastrointestinal disorders1/4480/453
Non-Cardiac Chest PainGeneral disorders1/4480/453
Bile Duct StoneHepatobiliary disorders1/4480/453
Biliary ColicHepatobiliary disorders1/4480/453
Escherichia SepsisInfections and infestations1/4480/453
Localised InfectionInfections and infestations1/4480/453
SepsisInfections and infestations1/4481/453
Most frequent other events
Most frequent other events
EventGroup 1: MenACYW Conjugate VaccineGroup 2: Menomune® Vaccine
Injection Site PainGeneral disorders113/44843/453
MyalgiaMusculoskeletal and connective tissue disorders98/44869/453
HeadacheNervous system disorders85/44866/453
MalaiseGeneral disorders65/44851/453
Injection Site ErythemaGeneral disorders23/4480/453

Baseline characteristics

Analysis was performed on all randomized participants.

Age, Continuous
Age, Continuous(years)Group 1: MenACYW Conjugate VaccineGroup 2: Menomune® VaccineTotal
Mean66.9 ± 7.5167.3 ± 7.5367.1 ± 7.52
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: MenACYW Conjugate VaccineGroup 2: Menomune® VaccineTotal
Female259261520
Male192194386
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: MenACYW Conjugate VaccineGroup 2: Menomune® VaccineTotal
American Indian or Alaska Native224
Asian516
Native Hawaiian or Other Pacific Islander011
Black or African American5447101
White389404793
More than one race000
Unknown or Not Reported101
09

Study locations

36 sites
  • Chandler, Arizona 85224, United States
  • Anaheim, California 92801, United States
  • San Diego, California 92103, United States
  • Waterbury, Connecticut 06708, United States
  • Clearwater, Florida 33756, United States
  • DeLand, Florida 32720, United States
  • Jacksonville, Florida 32205, United States
  • Jacksonville, Florida 32216, United States
  • Ponte Vedra, Florida 32081, United States
  • Port Orange, Florida 32127, United States
  • West Palm Beach, Florida 33409, United States
  • Lenexa, Kansas 66219, United States
  • Newton, Kansas 67114, United States
  • Wichita, Kansas 67205, United States
  • Elkridge, Maryland 21075, United States
  • Quincy, Massachusetts 02169, United States
  • Troy, Michigan 48098, United States
  • Saint Louis, Missouri 63141, United States
  • Endwell, New York 13760, United States
  • Greensboro, North Carolina 27408, United States
  • Raleigh, North Carolina 27612, United States
  • Winston-Salem, North Carolina 27103, United States
  • Fargo, North Dakota 58104, United States
  • Cincinnati, Ohio 45236, United States
  • Cincinnati, Ohio 45246, United States
  • Grants Pass, Oregon 97527, United States
  • Allentown, Pennsylvania 18012, United States
  • Uniontown, Pennsylvania 15401, United States
  • Mount Pleasant, South Carolina 29464, United States
  • Mount Pleasant, South Carolina 29646, United States
  • Dallas, Texas 75231, United States
  • Dallas, Texas 75234, United States
  • South Jordan, Utah 84095, United States
  • West Jordan, Utah 84088, United States
  • Charlottesville, Virginia 22911, United States
  • San Juan, 00918, Puerto Rico
10

References and documents

Publications

  • Esteves-Jaramillo A, Koehler T, Jeanfreau R, Neveu D, Jordanov E, Singh Dhingra M. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in >/=56-year-olds: A Phase III randomized study. Vaccine. 2020 Jun 9;38(28):4405-4411. doi: 10.1016/j.vaccine.2020.04.067. Epub 2020 May 6. PubMed 32387012 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Feb 2017, 6 months.

Results were first posted in Feb 2020, 3 years after primary completion. A results delay was requested in Feb 2018.

Of 25 phase 3 interventional studies under Meningitis, Meningococcal, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 20. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2016
First posted
Jul 25, 2016
StartActual
Jul 15, 2016
Primary completionActual
Feb 13, 2017
CompletionActual
Feb 13, 2017
Results delay requested
Feb 6, 2018
Results first posted
Feb 18, 2020
Last update
Apr 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02842866
Responsible party
Sponsor
First posted
Jul 25, 2016
Start date
Jul 15, 2016
Primary completion
Feb 13, 2017
Completion
Feb 13, 2017
Results posted
Feb 18, 2020
Last update
Apr 5, 2022

Study contacts

Medical Director
study director · Sanofi Pasteur Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion